https://crcblueprint.com/trials/a-study-of-amivantamab-and-folfiri-versus-cetuximab-bevacizumab-nct06750094/2026-08-07T13:50:45+00:00https://crcblueprint.com/trials/a-study-of-amivantamab-and-mfolfox6-or-folfiri-versus-nct06662786/2026-08-07T13:50:45+00:00https://crcblueprint.com/trials/a-study-to-evaluate-the-efficacy-and-safety-of-nct07284849/2026-08-07T13:50:45+00:00https://crcblueprint.com/trials/phase-iii-study-of-ivonescimab-or-bevacizumab-combined-with-nct07228832/2026-08-07T13:50:45+00:00https://crcblueprint.com/trials/a-study-to-evaluate-the-safety-and-efficacy-of-nct07221357/2026-08-07T13:50:45+00:00https://crcblueprint.com/trials/colon-adjuvant-chemotherapy-based-on-evaluation-of-residual-disease-nct05174169/2026-08-07T13:50:45+00:00https://crcblueprint.com/trials/a-clinical-study-of-calderasib-mk-1084-with-targeted-nct06997497/2026-08-07T13:50:45+00:00https://crcblueprint.com/trials/study-of-sotorasib-panitumumab-and-folfiri-versus-folfiri-with-nct06252649/2026-08-07T13:50:45+00:00https://crcblueprint.com/trials/a-study-to-access-intravenous-iv-telisotuzumab-adizutecan-in-nct07525206/2026-08-07T13:50:45+00:00https://crcblueprint.com/trials/a-study-of-precemtabart-tocentecan-with-or-without-bevacizumab-nct07549412/2026-08-07T14:20:44+00:00https://crcblueprint.com/trials/a-study-of-tucatinib-with-trastuzumab-and-mfolfox6-versus-nct05253651/2026-08-07T14:20:44+00:00https://crcblueprint.com/trials/testing-the-addition-of-total-ablative-therapy-to-usual-nct05673148/2026-08-07T13:50:45+00:00https://crcblueprint.com/trials/neoadjuvant-chemotherapy-excision-and-observation-vs-chemoradiotherapy-for-rectal-nct06205485/2026-08-07T14:20:43+00:00https://crcblueprint.com/trials/testing-pump-chemotherapy-in-addition-to-standard-of-care-nct05863195/2026-08-07T14:20:43+00:00https://crcblueprint.com/trials/bevacizumab-based-chemotherapy-adapted-to-bevacizumab-pharmacokinetics-in-1st-nct06642844/2026-08-07T14:20:43+00:00https://crcblueprint.com/trials/a-clinical-study-to-test-if-an-investigational-treatment-nct07079631/2026-08-07T14:20:43+00:00https://crcblueprint.com/trials/a-study-to-evaluate-the-adverse-events-and-efficacy-nct06820463/2026-08-07T14:20:43+00:00https://crcblueprint.com/trials/study-of-petosemtamab-plus-chemotherapy-versus-cetuximab-plus-chemotherapy-nct07702032/2026-08-07T14:20:43+00:00https://crcblueprint.com/trials/symbiotic-gi-03-a-study-to-learn-about-the-nct07222800/2026-08-07T14:20:43+00:00https://crcblueprint.com/trials/a-study-of-amivantamab-monotherapy-and-in-addition-to-nct05379595/2026-08-07T14:20:43+00:00https://crcblueprint.com/trials/ibi363-combined-with-bevacizumab-for-advanced-colorectal-cancer-nct07722494/2026-08-07T14:20:43+00:00https://crcblueprint.com/trials/study-of-xl092-atezolizumab-vs-regorafenib-in-participants-with-nct05425940/2026-08-07T14:20:43+00:00https://crcblueprint.com/trials/phase-3-study-of-mrtx849-with-cetuximab-vs-chemotherapy-nct04793958/2026-08-07T14:20:43+00:00https://crcblueprint.com/trials/a-study-to-evaluate-the-safety-and-efficacy-of-nct06948448/2026-08-07T14:20:44+00:00https://crcblueprint.com/trials/a-study-of-novel-study-interventions-and-combinations-in-nct06792695/2026-08-07T14:20:43+00:00https://crcblueprint.com/trials/randomizing-two-radiotherapy-boost-options-to-avoid-rectal-cancer-nct03051464/2026-08-07T14:20:43+00:00https://crcblueprint.com/trials/a-phase-2-study-of-vs-7375-in-patients-nct07659795/2026-08-07T14:20:43+00:00https://crcblueprint.com/trials/continuous-or-intermittent-cetuximab-plus-folfiri-as-first-line-nct07004413/2026-08-07T14:20:43+00:00https://crcblueprint.com/trials/study-of-denikitug-gs-1811-given-alone-or-with-nct07527858/2026-08-07T14:20:43+00:00https://crcblueprint.com/trials/a-study-comparing-bl-m07d1-with-physicians-choice-therapy-nct07730489/2026-08-07T14:20:43+00:00https://crcblueprint.com/trials/testing-the-effectiveness-of-the-anti-cancer-drug-pidnarulex-nct07147231/2026-08-07T14:20:43+00:00https://crcblueprint.com/trials/study-on-aspirin-versus-placebo-in-resected-colon-cancer-nct02945033/2026-08-07T14:20:43+00:00https://crcblueprint.com/trials/de-scalation-or-switch-of-treatment-according-to-circulating-nct06446557/2026-08-07T14:20:43+00:00https://crcblueprint.com/trials/a-study-testing-sot109-for-the-first-time-in-nct07693751/2026-08-07T14:20:43+00:00https://crcblueprint.com/trials/evaluation-of-co-formulated-pembrolizumab-quavonlimab-mk-1308a-versus-nct04895722/2026-08-07T14:20:43+00:00https://crcblueprint.com/trials/platform-study-of-circulating-tumor-dna-directed-adjuvant-chemotherapy-nct05534087/2026-08-07T14:20:43+00:00https://crcblueprint.com/trials/pm8002-bnt327-in-combination-with-chemotherapy-in-patients-with-nct07133750/2026-08-07T14:20:42+00:00https://crcblueprint.com/trials/a-study-to-assess-adverse-events-and-change-in-nct07023289/2026-08-07T14:20:42+00:00https://crcblueprint.com/trials/ctdna-based-adjuvant-chemotherapy-for-high-risk-rectal-cancer-nct07188025/2026-08-07T14:20:42+00:00https://crcblueprint.com/trials/a-study-to-test-dsp107-in-combination-with-atezolizumab-nct07235293/2026-08-07T14:20:42+00:00https://crcblueprint.com/trials/combination-chemotherapy-with-or-without-atezolizumab-in-treating-patients-nct02912559/2026-08-07T14:20:43+00:00https://crcblueprint.com/trials/testing-the-addition-of-atezolizumab-to-combination-chemotherapy-or-nct02997228/2026-08-07T14:20:43+00:00https://crcblueprint.com/trials/a-study-of-encorafenib-plus-cetuximab-taken-together-with-nct05217446/2026-08-07T14:20:43+00:00https://crcblueprint.com/trials/a-study-evaluating-the-safety-and-efficacy-of-targeted-nct04929223/2026-08-07T14:20:43+00:00https://crcblueprint.com/trials/efficacy-of-the-use-of-neoadjuvant-with-without-hyperthermic-nct06783491/2026-08-07T14:20:43+00:00https://crcblueprint.com/trials/beamion-bcgc-1-a-study-to-find-a-suitable-nct06324357/2026-08-07T14:20:43+00:00https://crcblueprint.com/trials/safety-of-hrx215-in-patients-after-minor-and-major-nct06638502/2026-08-07T14:20:43+00:00https://crcblueprint.com/trials/a-study-of-bispecific-antibody-mcla-158-in-patients-nct03526835/2026-08-07T14:20:43+00:00https://crcblueprint.com/trials/neoadjuvant-botensilimab-and-balstilimab-for-the-treatment-of-advanced-nct07595874/2026-08-07T14:20:42+00:00https://crcblueprint.com/trials/radiotherapy-systemic-therapy-as-conversion-therapy-for-pmmr-mss-nct06949111/2026-08-07T14:20:42+00:00https://crcblueprint.com/trials/a-phase-ii-clinical-trial-comparing-the-efficacy-of-nct04486378/2026-08-07T14:20:42+00:00https://crcblueprint.com/trials/a-clinical-study-of-mk-2870-alone-or-with-nct06428409/2026-08-07T14:20:42+00:00https://crcblueprint.com/trials/a-study-of-bms-986340-as-monotherapy-and-as-nct04895709/2026-08-07T14:20:42+00:00https://crcblueprint.com/trials/a-clinical-study-of-arfolitixorin-in-patients-with-mcrc-nct06922383/2026-08-07T14:20:42+00:00https://crcblueprint.com/trials/a-study-of-the-duration-of-dostarlimab-in-untreated-nct07740720/2026-08-07T14:20:42+00:00https://crcblueprint.com/trials/testing-the-addition-of-nivolumab-to-standard-treatment-for-nct05308446/2026-08-07T14:20:42+00:00https://crcblueprint.com/trials/scrt-chemo-targeted-immuno-neoadjuvant-therapy-for-high-risk-nct07549399/2026-08-07T14:20:42+00:00https://crcblueprint.com/trials/a-study-of-2nd-line-folfiri-%c2%b1-bevacizumab-vs-nct03303495/2026-08-07T14:20:42+00:00https://crcblueprint.com/trials/capecitabine-oxaliplatin-chemotherapy-and-cemiplimab-with-or-without-fianlimab-nct07281768/2026-08-07T14:20:42+00:00https://crcblueprint.com/trials/phase-i-ii-study-of-the-combination-immunotherapy-regimen-nct06149481/2026-08-07T14:20:42+00:00